BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 3:20 p.m. EST.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as RG7227 at Roche) that entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
InterMune, Inc.
